DYSF Expression: Biomarker in Clear Cell Renal Cell Carcinoma?
Posted: Monday, August 26, 2019
According to a retrospective study of two independent cohorts, conducted by Yun Hak Kim, MD, PhD, of the Pusan National University Hospital, Republic of Korea, and colleagues, expression of the gene DYSF may prove to be a useful prognostic biomarker for survival outcomes in patients with clear cell renal cell carcinoma. These findings, which were published in Urologic Oncology: Seminars and Original Investigations, warrant further studies to clarify the role of this gene in disease progression.
“These results suggested that DYSF may play a suppressive role in the progression of clear cell renal cell carcinoma and could act as a promising prognostic biomarker for predicting the survival of clear cell renal cell carcinoma patients,” the investigators concluded.
Data from 537 patients from The Cancer Genome Atlas (TCGA; n = 446) and International Genome Consortium (ICGC; n = 91) were assessed in this study. As calcium levels are known to affect patient prognosis, the investigators analyzed the efficacy of CaSR, GPRC6a, and DYSF.
Based on their research, DYSF was the only gene that seemed to be associated with survival in patients from both cohorts. The survival rate of patients with high DYSF expression was significantly higher than that of patients with low DYSF expression, despite generally higher levels of DYSF expression in tissue with clear cell renal cell carcinoma compared with tissue without it.
“We also validated the potential of DYSF as a prognostic biomarker for clear cell renal cell carcinoma by conducting a time-dependent area under the curve analysis and 5-year receiver operating characteristic curve analysis,” the investigators commented.
Disclosure: The study authors reported no conflicts of interest.